PET scans reveal how experimental drug targets scarred livers
NCT ID NCT07069725
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage study tests whether a single dose of the experimental drug AZD2389 can bind to a protein called FAP in the liver, which is linked to scarring. Twelve adults with advanced liver fibrosis will receive the drug and then have a PET scan to measure changes. The goal is to see if the drug reaches its target, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNSolna, 171 64, Sweden
-
Research Site
RECRUITINGStockholm, 17176, Sweden
Conditions
Explore the condition pages connected to this study.